Search Results for: tim melton stroke

KTRK's Tim Melton on the mend after stroke

Posted: Published on March 2nd, 2012

Longtime KTRK (Channel 13) sports reporter Tim Melton, who suffered a stroke last October, said today that he is continuing with rehabilitation work and feeling better and moving better. Tim Melton has been with Channel 13 since 1981.(handout) Melton posted an update on his Facebook page regarding his condition and confirming the nature of his illness. He said he has been undergoing treatment at the TIRR Memorial Hermann. I thank all of you who have expressed your concern as to what caused my absence, but I wanted to wait until I had a good sense of what the future holds before saying anything, he wrote. I am happy to report Im getting better every day. My thanks to all my friends at Channel 13 for their concern and support. Thanks to the doctors, therapists and nurses at TIRR. And special thanks to my sons and wife, who have had to go through the recovery with me and Im not always the greatest patient. Melton, who has been with Channel 13 since 1981, said he understands that viewers have been hungry for news of his condition. If theres not concern theres curiosity, and I appreciate those who are concerned. I even … Continue reading

Comments Off on KTRK's Tim Melton on the mend after stroke

Swapping just 100 calories of meat a day for a veggie substitute may help you live longer – here’s why – Melton Times

Posted: Published on March 13th, 2020

Swapping small amounts of meat for vegetarian substitutes may have a dramatic effect on our life expectancy, a new study suggests. Researchers have discovered that replacing just 100 calories worth of meat a day with plant protein has been linked to a 50 per cent decreased risk of death. Continue reading

Posted in Coronary Heart Diseases | Comments Off on Swapping just 100 calories of meat a day for a veggie substitute may help you live longer – here’s why – Melton Times

Epigenetic therapies for heart failure | VHRM – Dove Medical Press

Posted: Published on May 25th, 2021

Introduction Although novel drugs have successfully entered the clinical arena of heart failure with reduced ejection fraction (HFrEF), such as the PARADIGM-HF-derived angiotensin receptor neprilysin inhibitor (ARNI), disease-modifying therapies with a prognostic impact for patients affected by heart failure with preserved ejection fraction (HFpEF) are still lacking.15 HF is a complex and highly prevalent syndrome for which the heart undergoes a substantial structural remodeling in patients at risk for major cardiovascular diseases (CVDs) (Figure 1).16 Geneenvironment interactions can be mediated by specific patterns of epigenetic-sensitive changes (mainly DNA methylation and histone modifications) which may modulate the individual responsiveness to HF development.614 This complex molecular circuit seems to trigger early cardiomyocyte loss, cardiac-remodeling, and micro- and macrovascular damage contributing to the development of major CVDs which may lead to differential HF clinical phenotypes.614 Of note, the reversible nature of epigenetic-sensitive changes has been translated in the clinical management of specific hematological malignancies with the approval by the Food and Drug Administration (FDA) of some epidrugs, such as decitabine (Dacogen) and azacitidine (Vidaza), as DNA methylation inhibitors, as well as vorinostat (Zolinza), belinostat (Beleodaq), romidepsin (Istodax), and panobinostat (Farydak), as histone deacetylase inhibitors (HDACi).15 Epidrugs are now providing a novel vision for personalized therapy of HF and heart transplantation, opening up novel options for management of the affected patients.1518 At molecular level, we can classify the epidrugs in: direct epidrugs [eg, the bromodomain and extra-terminal (BET) protein inhibitor apabetalone]; and repurposed drugs with potential, indirect (non-classical) epigenetic-oriented interference by which they may exert cardioprotective functions [eg, hydralazine, metformin, statins, and sodium-glucose co-transporter-2 inhibitors (SGLT2i)] or nutraceutical compounds [eg, omega-3 polyunsaturated fatty acids (PUFAs)]. Encouraging results are coming from large randomized trials evaluating the putative beneficial effects of combining epidrugs with the conventional therapy in patients with HF.1422 Our goal is to update on the emerging epigenetic-based strategies which may be useful in the prevention and treatment of HFrEF and HFpEF (Figure 1). Continue reading

Posted in Ventricular Remodeling | Comments Off on Epigenetic therapies for heart failure | VHRM – Dove Medical Press